Live attenuated anterovirus vaccine (OPV) is not associated with islet autoimmunity in children with genetic susceptibility to type 1 diabetes : prospective cohort study by Viskari, Hanna et al.
Article 
Live attenuated enterovirus vaccine (OPV) is not associated with islet 
autoimmunity in children with genetic susceptibility to type 1 diabetes: 
prospective cohort study 
Hanna Viskari1,2, Sami Oikarinen1, Sanna Hoppu3, Tytti Vuorinen4,5, Heini Huhtala6, Jorma 
Toppari7,8, Riitta Veijola9, Jorma Ilonen10, Mikael Knip11–14, Heikki Hyöty1,15
1Department of Virology, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, 
Finland 
2Department of Internal Medicine, Tampere University Hospital, 33520 Tampere, Finland 
3Department of Intensive Care, Tampere University Hospital, Tampere, Finland 
4Department of Clinical Virology, Turku University Hospital, Turku, Finland 
5Department of Virology, University of Turku, Turku, Finland 
6Faculty of Social Sciences, University of Tampere, Tampere, Finland 
7Department of Physiology, Institute of Biomedicine, University of Turku, Turku, Finland 
8Department of Pediatrics, Turku University Hospital, Turku, Finland 
9Department of Pediatrics, PEDEGO Research Unit, Medical Research Center, Oulu University 
Hospital and University of Oulu, Oulu, Finland 
10Immunogenetics Laboratory, University of Turku and Turku University Hospital, Turku, Finland 
11Children’s Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland 
12Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland 
13Department of Pediatrics, Tampere University Hospital, Tampere, Finland 
14Folklhälsan Research Center, Helsinki, Finland 
15Fimlab Laboratories, Pirkanmaa Hospital District, Tampere, Finland 
Corresponding author: 
Hanna Viskari 
Department of Internal Medicine, Tampere University Hospital, 33520 Tampere, Finland 
Email: hanna.viskari@uta.fi 
Received: 23 May 2017 / Accepted: 10 July 2017 
This is the post print version of the article, which has been published in Diabetologia. 2018, 61(1), 
203–209. http://dx.doi.org/10.1007/s00125-017-4410-4
Abstract 
Aims/hypothesis Animal and human studies have implied that enterovirus infections may modulate 
the risk of islet autoimmunity and type 1 diabetes. We set out to assess whether serial administration 
of live oral poliovirus vaccine (OPV) in early life can influence the initiation of islet autoimmunity 
in a cohort of genetically predisposed children. 
Methods OPV was administered to 64 children and a further 251 children received inactivated 
poliovirus vaccine (IPV). The emergence of type 1 diabetes-associated autoantibodies in serum 
(autoantibodies to GAD, insulinoma-associated protein 2, insulin and islet cells) was monitored 
during prospective follow-up. Stool and serum samples were collected for enterovirus detection by 
RT-PCR. 
Results Administration of OPV increased enterovirus detected in stool samples from 11.3% to 38.9% 
(p<0.001) during the first year of life. During the follow-up (median 11.0 years), at least one 
autoantibody was detected in 17.2% of children vaccinated with OPV and 19.1% with IPV (p=0.723). 
At least two autoantibodies were observed in 3.1% and 6.8% of children, respectively (p=0.384). 
Conclusions/interpretation Replication of attenuated poliovirus strains in gut mucosa is not 
associated with an increased risk of islet autoimmunity. 
Trial registration ClinicalTrials.gov: NCT02961595 
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Introduction 
Enteroviruses have been associated with type 1 diabetes in several studies [1,2]. These viruses have 
become increasingly interesting targets of potential preventive interventions in type 1 diabetes [3], 
and clinical trials with enterovirus vaccines would be needed to evaluate a possible causal 
relationship. Both live attenuated and inactivated enterovirus vaccines have long been used against 
polioviruses, the well-known examples of enteroviruses. Regarding other enteroviruses, vaccines 
against enterovirus 71 have passed phase III trials only recently [4]. 
The disease process leading to type 1 diabetes is usually slow. Disease-associated autoantibodies 
which target pancreatic islet autoantigens and predict the development of type 1 diabetes are the first 
detectable markers of the initiation of this process [5,6]. These autoantibodies often appear at young 
age. In a recent report that combined data from three birth cohort studies from Colorado (USA), 
Germany and Finland, the median age at the appearance of multiple islet autoantibodies was only 2.1 
years, while clinical diabetes was diagnosed at a median age of 6.1 years [5]. Genetic susceptibility 
to the disease is regulated mainly by the genes in the HLA locus but also by several non-HLA genes, 
most of which are involved in the regulation of the immune responses [7]. 
Environmental factors play an important role in the pathogenesis of type 1 diabetes and the most 
studied candidates include enteroviruses. These viruses are among the most common viruses to infect 
humans worldwide and include more than 100 genotypes (human enterovirus species A–D) [8,9]. 
Infections have a seasonal pattern, especially in temperate countries such as Finland, peaking in the 
summer and autumn. Collectively, enteroviruses can infect almost all human tissues but various 
genotypes have specific tropism to certain organs and cells, which is partly regulated by the 
attachment of different viruses to different host cell receptors [8]. For example, polioviruses show 
neurotropism by attaching to specific poliovirus receptors in the anterior spinal cord. Furthermore, 
certain enterovirus types have tropism to human pancreatic islets causing islet damage and 
inflammation during infection [10]. Enterovirus protein has been detected in pancreatic islets in the 
majority of individuals with type 1 diabetes [11]. 
Poliovirus vaccines offer a useful model for the development of vaccines against other enteroviruses. 
Two types of poliovirus vaccines, the inactivated (IPV) and the live attenuated ‘oral’ (OPV) vaccines, 
have been used worldwide since the mid-20th century. IPV contains formalin-inactivated polioviruses 
and is administered by parenteral injection leading to immunisation, whereas OPV includes infective 
but attenuated viruses that are administered orally leading to subclinical infection in vaccine 
recipients. OPV is highly immunogenic inducing humoral and cell-mediated antiviral immune 
responses and mucosal immunity, while IPV induces mainly humoral immune responses. Both are 
generally safe but OPV may rarely cause prolonged infection or major adverse effects especially in 
immunocompromised recipients [9]. 
A possible association between poliovirus vaccinations and the risk of type 1 diabetes or development 
of islet autoantibodies has been analysed in a few studies [12-14]. However, these studies have not 
distinguished between IPV and OPV. Nevertheless, no indication of an increased risk of type 1 
diabetes or islet autoimmunity has been seen in individuals vaccinated against polio. Since OPV 
induces a stronger immune response than IPV and inflammation in the gut mucosa, and might thus 
change the immunological milieu in the closely located pancreas and its lymphatic networks, we 
carried out a study to test whether children who are exposed to live attenuated poliovirus by serial 
OPV administration early in life have a distinct risk of developing diabetes-associated autoantibodies 
compared with children vaccinated with IPV. 
Methods 
Participants This study was carried out in a birth cohort of the ongoing prospective Type 1 Diabetes 
Prediction and Prevention (DIPP) study in Tampere, Finland, as previously described [15,16]. 
Briefly, all babies whose parents gave informed consent to participate in the study were first screened 
for HLA class II alleles conferring susceptibility to type 1 diabetes (HLA type was analysed from 
cord blood) and those with increased risk were recruited to the prospective follow-up study [15,16]. 
A group of 64 children (34 boys) from the DIPP study whose parents consented to the OPV trial 
presented here were vaccinated using four serial doses of OPV (Polio Sabin, SB Biologicals, 
Rixensart, Belgium) at the age of 2, 3, 6 and 12 months (two drops in each oral dose). OPV included 
attenuated replication competent strains of the three poliovirus types (polioviruses 1, 2 and 3). All 
these children carried HLA-DQB1 alleles conferring moderately increased risk for type 1 diabetes 
(HLA-DQB1×0302/x, x≠DQB1×0201, ×0301, ×0602). A comparison group of 251 children received 
non-adjuvanted IPV [17] at their well baby clinic at the age of 6 and 12 months according to the 
standard national immunisation programme in Finland at that time (Fig. 1). All 64 children in the 
OPV group received a complete set of four serial vaccinations as planned, and there were no vaccine 
refusals among the IPV group either. After the age of 12 months both groups were recommended to 
continue according to the national immunisation programme with IPV at the age of 2, 6 and 9–12 
years. Both groups were recruited at the same DIPP study centre in the Tampere University Hospital 
during the same time period (1999–2000), thus they were all exposed to the same enterovirus seasons 
at the same age. 
Islet autoantibody analyses All children were observed regularly from birth with blood samples 
taken at 3, 6, 9, 12, 18 and 24 months and at 12 month intervals thereafter for the analyses of islet 
autoantibodies. Islet autoantibodies were analysed from serum or plasma and included insulin 
autoantibodies (IAA), islet cell antibodies (ICA), insulinoma-associated protein 2 antibodies (IA-2A) 
and GAD antibodies (GADA) as previously described [16,18]. Positivity for multiple autoantibodies 
was defined as positivity for at least two of these autoantibodies during the whole follow-up period. 
Transient autoantibody positivity was defined as one or more positive samples, followed by at least 
two negative samples. Persistent autoantibody positivity was defined as at least two positive samples 
in a row, including the last sample obtained. Samples with maternal autoantibodies (antibodies 
detected initially in cord blood with decreasing levels in subsequent samples maximally up to the age 
of 15 months) were not included in the analyses. Clinical type 1 diabetes was diagnosed according to 
the ADA criteria. 
Neutralising poliovirus antibodies Neutralising antibodies against poliovirus types 1–3 were 
analysed using the plaque assay to assess vaccine-induced immunity from plasma samples collected 
at 24 months from 64 children from each vaccine group (if a sample was not available at 24 months 
the previous sample was tested). The polioviruses (Sabin strains) were first incubated with ¼ or 1/64 
dilution of plasma for 1 h at 36°C followed by an overnight incubation at room temperature using a 
method described previously [19]. The virus was then added on monolayers of Green Monkey kidney 
cells on six-well plates (Nunclon, NUNC, Denmark). The amount of infectious virus was measured 
by counting the plaques after 46 h of incubation at 36°C. The plasma was taken as antibody positive 
if it blocked >85% of the virus infectivity. 
Detection of enterovirus RNA Stool samples were collected monthly at 3–24 months from all 
children in the OPV group and from 64 children in the IPV group. Thus, samples were taken 
sequentially at the same age forming a series of comparable samples in both groups. First a 10% stool 
suspension was prepared from the original stool sample in Hanks’ solution including gentamycin, 
penicillin G, amphotericin B and 4% BSA. QIAamp viral RNA kit (Qiagen, Hilden, Germany) was 
used to extract the viral RNA. Stool samples were systematically screened for the presence of 
enterovirus and rhinovirus RNA using RT-PCR as previously described [20, 21]. This method 
amplifies a 115 bp long fragment of 5’UTR of the viral genome which is common for all enteroviruses 
and rhinoviruses. The amplicons were linearly quantified with a liquid hybridisation assay using 
probes that detected either enterovirus or rhinovirus specific sequences. All positive samples were 
retested and all test runs included one virus positive control and two virus negative control samples. 
The analyses were carried out blind without knowing the vaccination history of the child, but the 
samples from the different vaccination groups were analysed in the same test runs. 
Altogether 325 plasma samples from these children were analysed for the presence of enterovirus 
RNA using the same RT-PCR method (163 samples from the OPV group and 162 from the IPV 
group). These plasma samples were collected at 3–24 months of age and one to six samples were 
taken for each child (mean 2.5 samples per child in both groups). RNA extraction was performed 
from 500–1000 µl of serum using the QIAamp UltraSens Virus Kit (Qiagen). 
A restriction enzyme analysis was performed for PCR amplicons of all enterovirus-positive samples 
in order to distinguish OPV-derived poliovirus strains from non-polio enterovirus strains. At least 
one virus sequence of all available human enterovirus strains were obtained from GenBank for 
restriction site screening (218 strains in total). The specific restriction enzymes for Sabin strains were 
identified using the GeneDoc programme from the REBASE restriction enzyme collection [22,23]. 
The PCR amplicons of the Sabin 1 strain were cut with AvaI, Sabin 2 with AlwNI and Sabin 3 with 
PvuII in silico and laboratory tests. PCR amplicons of only one of the three tested Coxsackievirus 
A20 strains was cut with AlwNI, while none of the other non-polio enterovirus strains was cut with 
the selected poliovirus-specific enzymes. The restriction reactions were performed using 10 µl of the 
PCR product according to manufacturer’s protocol. The quantification of the uncut PCR product after 
restriction was performed with liquid phase hybridisation and the signal was compared with the signal 
of the original PCR product. 
Statistical analyses The χ2 test and Fisher’s exact test were used to analyse the statistical significance 
of differences observed between the children vaccinated with OPV and IPV. Kaplan–Meier survival 
analysis was carried out to assess the time to autoantibody positivity. The difference between follow-
up times was analysed with the Mann–Whitney U test. Cox regression was used to adjust for 
differences in number of siblings, pets in the family home and nursery/childcare attendance after 12 
months of age between those receiving IPV vs OPV. The software packages used were SPSS version 
22.0 (SPSS, Armonk, NY, USA) and Stata version 13.1 (StataCorp, College Station, TX, USA). 
Differences were considered significant at p<0.05. 
Ethics The study was approved by the Pirkanmaa Hospital District Ethical Committee and the 
National Agency for Medicines in Finland (97193M KnipM, 98203M KnipM, clinicaltrials.gov: 
NCT02961595). Parents or guardians expressed their consent in writing. 
Results 
Both OPV and IPV induced clear immune responses to each of the three poliovirus types. All 64 
children who received OPV developed neutralising antibodies to all the three poliovirus types (1/4 
titre). However, two of the 64 children in the IPV group who were tested for poliovirus antibodies 
remained negative for neutralising antibodies against poliovirus type 1 and one child remained 
negative for antibodies against poliovirus type 3. The two children negative for poliovirus 1 lacked a 
plasma sample for 24 months and antibodies were analysed from earlier time points (9 months and 
12 months) when they had received only one dose of IPV. The one child negative for poliovirus 3 
was analysed at 24 months. High antibody titres (>1/64) against all poliovirus types 1–3 at 24 months 
were detected in 92% (46/50) of the children in the OPV group compared with 62% (31/50) of those 
in the IPV group (p=0.001). The high antibody titres against poliovirus 1, 2 and 3 were observed in 
96%, 100% and 96% of the children vaccinated with OPV compared with 88% (p=0.26), 90% 
(p=0.56) and 72% (p=0.002) of those vaccinated with IPV, respectively. 
Enterovirus RNA was detected in 29.7% of the 744 stool samples collected from 3 to 24 months of 
age from children in the OPV group compared with 12.0% of the 744 stool samples from children in 
the IPV group (p<0.001). This difference was seen in samples (470 in both groups) taken before the 
age of 12 months (38.9% vs 11.3%; p<0.001) but not in later samples (8.1% vs 7.7%). The restriction 
enzyme analyses confirmed the presence of Sabin poliovirus vaccine strains in 58.5% (107/183) of 
the enterovirus-positive samples in the OPV group, while no polioviruses were detected in the IPV 
group. Only one child in the OPV group did not have detectable enterovirus in stool samples but there 
were only three stool samples available from this child. Consequently, 98.4% (63/64) of the children 
vaccinated with OPV had enterovirus-positive stool samples during the first year of life compared 
with 43.8% (28/64) of children vaccinated with IPV (p<0.001). No difference was seen in rhinovirus 
positivity between the OPV and IPV groups (9.9% vs 9.8% of stool samples were positive for 
rhinovirus RNA, respectively). Enterovirus RNA was detected in plasma in only three of the children 
in the OPV group and in three children in the IPV group (in 1.8% of the samples). 
Altogether 4358 serum samples were analysed for diabetes-associated islet autoantibodies by 
December 2015. The median follow-up time from birth to the last serum sample was 11.0 years and 
the total number of follow-up years was 3015.5 years. The follow-up time was at least 5 years in 75% 
of the OPV group and 68.9% of the IPV group. A follow-up time of 10 years and 15 years was 
completed in 50% and 30% of the children in the OPV group and in 52.6% and 25.9% of the children 
in the IPV group, respectively (electronic supplementary material [ESM] Fig. 1). 
At least one autoantibody was detected at least once in 59 (18.7%) children, with no difference 
between the groups (Table 1). This was true both among boys and girls. The first islet autoantibodies 
appeared at the median age of 6.1 years (range 0.7–11.9 years) in children who received OPV 
compared with 5.0 years (range 0.2–14.2 years) in children who received IPV. Kaplan–Meier survival 
analysis did not show any difference in the time from birth to the first autoantibody positivity between 
the vaccination groups (p=0.616, Fig. 2). The result remained the same after adjusting for sex, number 
of siblings, whether the household had pets and whether the child had started attending 
childcare/nursery before the age of 13 months. No difference was seen in the appearance of persistent 
islet autoantibodies (p=0.922, ESM Fig. 2) or multiple autoantibodies between children vaccinated 
with IPV and OPV. Two or more different islet antibodies were observed in two children vaccinated 
with OPV (3.1%, both boys) at the ages of 1.5 and 8.9 years. In the IPV group, multiple autoantibodies 
were detected in 17 children (6.8%, ten boys) at a median age of 4.9 years (range 0.6–12.0 years) 
(Table 1). Persistently positive multiple islet antibodies were detected in only one (1.5%) child 
vaccinated with OPV and eight (3.2%) children vaccinated with IPV at a median age of 2.6 years 
(range 0.8–11.1 years). There was no difference between the vaccination groups (OPV vs IPV) in the 
frequency of the first appearing autoantibody as IAA (3.1% vs 4.4%), IA-2A (3.1% vs 2.0%) or 
GADA (1.6% vs 2.4%). Maternal autoantibodies (antibodies in cord blood) were detected in two 
children, the follow-up samples were persistently negative in one child while the other developed 
ICA and IAA at 8 years of age. 
Only one child (1.6%) in the OPV group developed clinical type 1 diabetes at the age of 2.9 years. 
Four children (1.6%) in the IPV group developed clinical diabetes at a mean age of 6.9 years (range 
3.0–10.0 years). The children progressing to type 1 diabetes had been repeatedly positive for multiple 
islet autoantibodies. 
Discussion 
Animal and human studies have shown that enterovirus infections may be involved in the 
pathogenesis of type 1 diabetes and a vaccine against potentially diabetogenic enterovirus strains 
would thus provide important information in the evaluation of causality. However, there have been 
concerns that immunisation against enteroviruses could induce islet autoimmunity and that vaccines 
could thus increase the risk of type 1 diabetes. For example, both inactivated and live attenuated 
vaccines could contain viral epitopes that are able to induce immunological cross-reactivity against 
beta cell proteins. Furthermore, live vaccines that cause an infection in vaccine recipients could 
induce beta cell damage by some additional mechanism. One such mechanism is related to the 
inflammation response that is induced by the replication of vaccine virus strains in the recipients. 
Live enterovirus vaccines that contain infectious viruses can lead to prolonged replication of vaccine 
virus strains in the intestinal mucosa and gut-associated lymphoid tissue. The close anatomical 
location of the pancreas and common lymphatic and vascular networks in this region may facilitate 
the spread of vaccine-induced inflammation from the intestine to the pancreas via soluble factors and 
activated lymphoid cells. 
The results of the present study clearly show that sequential exposure to OPV significantly increased 
the detection of enterovirus RNA in stool samples. The rate of enterovirus positivity in stool samples 
in the IPV group was well in line with our earlier findings in Finnish children [24]. When compared 
with the IPV group, the children vaccinated with OPV had almost four times more enterovirus-
positive stool samples at the age when OPV was administered (<1 year of age) and this excess was 
due to increased detection of polioviruses. This indicates that OPV caused a marked increase in 
enterovirus exposure in the participating infants. Since these vaccine strains replicate in the gut 
administration also leads to inflammation and stimulates the gut-associated immune system that has 
been proposed to regulate the development of islet autoimmunity [25]. However, we did not find any 
evidence that this could have clearly increased or decreased the risk of islet autoimmunity. Our 
findings support earlier studies showing that poliovirus vaccines do not correlate with the appearance 
of islet autoantibodies or clinical type 1 diabetes [12-14]. In addition, this study shows that the type 
of vaccine (OPV or IPV) does not contribute to the risk. Moreover, the results are in line with 
epidemiological observations suggesting that type 1 diabetes incidence has mostly been lower in 
countries using OPV compared with countries using IPV [26,27]. 
Both OPV and IPV induced neutralising antibodies but OPV induced stronger responses than IPV. 
This is logical since the children in the OPV group had received four vaccinations by the time 
neutralising antibodies were analysed compared with two vaccinations in the IPV group. The rate of 
enterovirus viremia was not higher in the OPV group compared with the IPV group. This probably 
reflects the attenuated nature of OPV vaccine virus strains as attenuated viruses replicate more slowly 
and cannot reach the blood during the first few days while the neutralising antibodies are not yet in 
place. 
The children in the two study groups were purposefully very similar. The time of birth and 
geographical location were comparable between the groups; therefore, the children were exposed to 
the same enterovirus seasons and same kinds of enteroviruses circulating in their living environment. 
The children in both groups were also similar for their type 1 diabetes-associated HLA alleles that 
are known to affect the appearance of disease-associated autoantibodies [7]. Thus, it is unlikely that 
these factors could have biased the evaluation of association between OPV and IPV, and the risk of 
islet autoimmunity and type 1 diabetes. However, there are also some limitations in this study. First, 
this was not a randomised study but an open cohort study in a ‘real-life setting’. In addition, the 
number of children receiving OPV was relatively small (n=64) in line with the pilot-type design of 
this study. However, despite the relatively small number of children, the follow-up period was long 
(median 11.0 years). Altogether 88% of the children were observed for at least 2 years, which is the 
median age when multiple islet antibodies appeared in the Finnish children [5]. Moreover, 81% the 
of children were followed for at least 3 years, at which time, according to previous data from the 
DIPP study, 82% of children who later develop clinical type 1 diabetes already have seroconversion 
to positive islet autoantibodies [28]. The appearance of islet antibodies in the IPV group was similar 
to that previously seen in Finnish children with comparable HLA backgrounds [6]. However, it should 
be noted that the size of this study cohort limits the power to detect possible subtle differences 
between the groups. 
In conclusion, this study suggests that the risk of islet autoimmunity does not differ between children 
vaccinated with OPV vs IPV. This indicates that the replication of attenuated enterovirus strains in 
the intestine does not increase the risk of type 1 diabetes. 
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Fig. 1 Schematic presentation of the study protocol. Black and white arrows show the time of OPV 
and IPV administration, respectively. Black dots show the timing of the first six serum sample 
collections. White dots show the timing of stool sample collection every month from 3 to 24 months 
Fig. 2 Kaplan–Meier analysis of the time (years) from birth to the emergence of the first diabetes-
associated islet autoantibody in 64 children who received OPV (black line) and in 251 children who 
received IPV (grey line). p=0.616 
 
Table 1 Emergence of diabetes-associated islet autoantibodies in 64 children who received OPV and in 251 children who received IPV 
  Type of vaccine  p value 
OPV 
n=64 
IPV 
n=251 
Boys, n  34 123   
Median follow-up years from birth (range)  10.9 (1.0–15.2) 11.1 (0.5–15.9)  0.969 
Median number of serum samples (range)  15 (4–24) 15 (2–38)  0.990 
Median number of stool samples (range)   11 (2–20) 11 (2–20)  1.000 
Enterovirus-positive stool samples, n (%)  221 (29.7) 89 (12.0)  <0.001 
Seropositive for all polioviruses 1–3, n (%)  64 (100) 61 (95.3)  0.244 
Clinical type 1 diabetes, n (%)  1 (1.6) 4 (1.6)  1.000 
At least one autoantibodya, n (%)  11 (17.2) 48 (19.1)  0.723 
Persistently positive autoantibodiesb, n (%)  4 (6.3) 16 (6.4)  0.971 
Transiently positive autoantibodiesc, n (%)  7 (10.9) 36 (14.3)  0.479 
At least two autoantibodies (2–4), n (%)  2 (3.1) 17 (6.8)  0.384 
Two or three autoantibodies excluding ICA, n (%)  1 (1.6) 10 (4.0)  0.701 
Individual autoantibodies, n (%)      
  ICA  10 (15.6) 48 (19.1)  0.519 
  IAA  2 (3.1) 14 (5.6)  0.541 
  GADA  1 (1.6) 12 (4.8)  0.479 
  IA-2A  2 (3.1) 9 (3.6)  1.000 
All children carry moderate HLA-conferred susceptibility to type 1 diabetes (HLA-DQB1×0302/x, x≠×DQB1 0201, ×0301, ×0602) 
aAt least one autoantibody detected in any of the follow-up serum samples, maternal autoantibodies not included 
bAt least two positive samples in a row, including the last sample obtained, implying that the last sample had to be positive 
cOne or more positive samples, followed by at least two negative samples 
Fig 1. Schematic presentation of the study protocol. Black arrows show the time of OPV 
vaccination and the white arrows the time of IPV vaccination. Black dots show the timing 
of the first six serum samples. Stool samples (white dots) were collected every month 
from 3 months to 2 years. 
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Fig. 2 Kaplan–Meier analysis of the time (years) from birth to the emergence of the first 
diabetesassociated islet autoantibody in 64 children who received OPV (black line) and in 
251 children who received IPV (grey line). p=0.616
